PDAC

Disease

Disease Profile

PDAC stands for pancreatic ductal adenocarcinoma, the predominant histologic type of pancreatic cancer with aggressive biology and poor survival.

Category: pancreatic adenocarcinoma
Prevalence: PDAC represents about 90% of pancreatic cancer cases.

Related News

Revolution Medicines Begins Phase 3 Trial for Daraxonrasib in First-Line Pancreatic Cancer

Apr 03, 2026

Revolution Medicines has initiated patient treatment in the Phase 3 RASolute 303 trial testing daraxonrasib as first-line therapy for metastatic pancreatic cancer. The company also expects top-line data from its Phase 3 RASolute 302 trial in second-line pancreatic cancer in the first half of 2026. Both trials are evaluating the oral RAS(ON) inhibitor in pancreatic ductal adenocarcinoma, a highly lethal cancer with significant unmet medical need.

Biotech M&A Targets Focus on Late-Stage GLP-1, Oncology and CNS Assets

Apr 02, 2026

Pharmaceutical M&A is shifting toward late-stage clinical assets with proven human data, particularly in GLP-1 obesity drugs, oncology, and central nervous system disorders. Companies like Viking Therapeutics, Structure Therapeutics, and Revolution Medicines represent compelling acquisition targets with advanced clinical programs. This trend reflects industry prioritization of de-risked assets that can accelerate commercialization pathways.

Xenetic Biosciences Reports 2025 Results; Xeris Biopharma Schedules Earnings Release

Mar 13, 2026

Xenetic Biosciences reported a net loss of $2.7 million for 2025 while advancing its DNase-based cancer therapy toward clinical trials, ending the year with $7.9 million in cash. Xeris Biopharma will announce its 2025 financial results on March 2, 2026.

FDA Expedites Review of Daraxonrasib for Pancreatic Cancer Treatment

Mar 12, 2026

The FDA is accelerating its review of daraxonrasib, a targeted therapy for pancreatic cancer, under a new pilot program that could reduce approval time from 10-12 months to one to two months.

AI Tool Predicts Optimal Chemotherapy for Advanced Pancreatic Cancer Patients

Mar 04, 2026

A computational histology artificial intelligence platform can predict which of two chemotherapy regimens is more effective for individual pancreatic cancer patients, according to a study published in the Journal of Clinical Oncology.

Candel Therapeutics Secures $100M Royalty Funding from RTW for Prostate Cancer Therapy

Feb 20, 2026

Candel Therapeutics announced a $100 million royalty funding agreement with RTW Investments, contingent on FDA approval of aglatimagene besadenovec for intermediate- to high-risk localized prostate cancer, with tiered royalties on U.S. net sales.

Pancreatic Cancer Precision Medicine Market to Reach $2.5 Billion by 2033

Feb 17, 2026

The global pancreatic cancer precision medicine market is projected to grow from US$ 610 million in 2024 to US$ 2,467.83 million by 2033 at a 16.8% CAGR, driven by advances in targeted therapies, genomic diagnostics, and liquid biopsies.

Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep in Colorectal Cancer

Feb 16, 2026

Oncolytics Biotech received FDA Fast Track Designation for pelareorep in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, based on clinical data showing a 33% response rate and median survival of 27 months versus 11.2 months with standard treatment.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07573215	Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma	AVAILABLE
NCT07562152	Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma	RECRUITING	PHASE3
NCT07491445	Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma	RECRUITING	PHASE3
NCT07490301	A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma	NOT_YET_RECRUITING	PHASE2/PHASE3
NCT07441174	IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors	RECRUITING	PHASE1/PHASE2
NCT07349537	Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors	RECRUITING	PHASE1
NCT07259590	A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation	RECRUITING	PHASE1/PHASE2
NCT07252232	Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)	RECRUITING	PHASE3
NCT07198321	A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07145450	Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC	RECRUITING	PHASE1/PHASE2